Takeda expects the 52-week data to be available later this year. "For Patients With Rare Blood Cancer, New Drug Offers Relief," at 10 a.m. ET on June 9, incorrectly said the company expected the data around the spring of 2026.
(END) Dow Jones Newswires
June 10, 2025 14:03 ET (18:03 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.